find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
351
Clinical Trials
DNA
N/A
Enrolling
nct/study# N/A / GENE-ALTERATION-DIFFERENCES
Gene Alteration Differences in Patients with Solid Cancer between Hispanic and Non-Hispanic Population
Learn More
Advanced Solid Tumors
Phase I
Enrolling
nct/study# NCT05836324 / INCA33890-101
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Learn More
Solid Tumors
Phase I
Enrolling
nct/study# NCT06179160 / INCB161734-101
Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors with KRAS G12D Mutation.
Learn More
Advanced Solid Tumors
Phase I
Enrolling
nct/study# NCT06792552 / SIM0505-101
A PHASE I FIRST-IN-HUMAN, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF SIM0505 IN ADULT PARTICIPANTS WITH ADVANCED SOLID TUMORS
Learn More
Advanced Solid Tumors
Phase I/II
Enrolling
nct/study# NCT05584670 / TCD17620
A Phase 1/2, open label, first-in-human, dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of SAR445877 administered as monotherapy in adults with advanced solid tumors
Learn More
Advanced Solid Tumors
Phase I
Enrolling
nct/study# NCT06276491 / XMAB541-01
A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb®541 in Advanced Solid Tumors
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.